Our News
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.
Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.
Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.


5 September 2023 – Yourgene Health Launches MagBench Automated DNA Extraction Instrument and Kit for NIPT Workflows
The collaborative study with Tommy’s Charity and St Mary’s NHS Hospital (Manchester, UK) used Yourgene’s IONA® Nx NIPT Workflow, a fully validated clinical workflow which utilises NGS to estimate the trisomy risk in the fetus.

19 June 2023 – Yourgene Health Presents Data Demonstrating Successful Fetal Fraction Enrichment in NIPT Workflows Following Prolonged Blood Storage in EDTA Tubes
The collaborative study with Tommy’s Charity and St Mary’s NHS Hospital (Manchester, UK) used Yourgene’s IONA® Nx NIPT Workflow, a fully validated clinical workflow which utilises NGS to estimate the trisomy risk in the fetus.

22 May 2023 – Directorate Change
Yourgene announces the reappointment of Dr. Joanne Mason, Chief Scientific Officer, as a Director of the Company with immediate effect.

22 May 2023 – Yourgene Genomic Services to support MHC’s Boots agreement
Yourgene has entered into an agreement via its subsidiary Concepta Diagnostics Limited with Boots UK Limited (“Boots”), the health and beauty retailer and pharmacy group, to launch its extended range of at-home self-testing products tests via boots.com and across 120 Boots stores in Great Britain and Northern Ireland.

25 January 2023 – Directorate Change
Andy Leeser is one of the UK’s most experienced mid-market corporate transformation specialists. He has been involved with a range of transformation projects and transactions, including refinancings and equity/ asset sales across the Automotive, Oil and Gas, Brewing, Retail and Telecommunications sectors.

25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Notice of AGM, Change of Registered Address and Investor Presentation Manchester, UK – 25 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics...

16 August 2022 – Open Day and advance notice of AGM
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Open Day and advance notice of AGM Manchester, UK – 16 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be hosting an Open Day at its new facilities on Manchester...

27 July 2022 – Audited Final Results
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Audited Final Results Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its final results for the financial year ended 31 March...

27 July 2022 – Dr John Brown CBE confirmed as Chairman
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Dr John Brown CBE confirmed as Chairman Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, confirms the appointment of Dr John Brown CBE as Chairman...

24 May 2022 – Launch of the Accelerator Phase for Microdeletions Plugin
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of the Accelerator Phase for Microdeletions Plugin Expanding the clinical menu and capabilities of IONA® Nx NIPT Workflow offering Manchester, UK – 24 May 2022: Yourgene (AIM: YGEN), a...

26 April 2022 – Full year trading update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Full year trading update Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides the following unaudited trading update for the year ended 31...

26 April 2022 – Directorate Change
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate Change Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that after a five-year tenure, Adam Reynolds will step down from...

25 April 2022 – Strategic partnership extended with Ambry Genetics
Yourgene Health plc (“Yourgene” or the “Company”) Strategic partnership extended with Ambry Genetics Expanding market access of technology Manchester, UK – 25 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company...

06 April 2022 – Capital Markets Day
Yourgene Health plc (“Yourgene” or the “Company”) Capital Markets Day Manchester, UK – 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April...

17 February 2022 – Successful CTDA desktop review
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Successful CTDA desktop review Approval for sale of Clarigene® SARS-CoV-2 Test in the UK Manchester, UK - 17 February 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group,...

25 January 2022 – Directorate Change
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate Change Manchester, UK - 25 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the appointment of Mary Tavener as a Non-executive Director...

19 January 2022 – Opening of new Yourgene Health Canada Inc. facilities
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Opening of new Yourgene Health Canada Inc. facilities Supporting future growth for Ranger® Technology Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), the international molecular diagnostics...

19 January 2022 – Agreement of new debt facility
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Agreement of new debt facility Silicon Valley Bank facility to provide non-dilutive funding for accretive growth opportunities Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), a leading...

18 January 2022 – US partnership with EKF Diagnostics for NIPT and additional genomic tests
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) US partnership with EKF Diagnostics for NIPT and additional genomic tests Collaboration with EKF Diagnostics to use its accredited US laboratories for NIPT and Oncology testing Manchester, UK – 18...

17 January 2022 – Current year trading update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Current year trading update Further upgrade to full year revenue guidance following strong trading performance Manchester, UK – 17 January 2022: Yourgene (AIM: YGEN), the international molecular...

23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DHSC contract awarded to support COVID-19 Winter surge testingThird contract awarded under PHE National Microbiology Framework Agreement Manchester, UK – 23 December 2021: Yourgene (AIM: YGEN), a leading...

14 December 2021 – Half-year Report
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) H1 revenues doubled year-on-yearFull year revenues to exceed already upgraded market expectations Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading integrated technologies and service...

14 December 2021 – UKHSA contract award
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) UKHSA contract awardContract for the provision of the genetic sequencing services Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces...

18 November 2021 – DPYD screening recommended in Spain
Yourgene Health plc(“Yourgene” or the “Company”) DPYD screening recommended in SpainFollows recommendations in Germany, Wales, England and Belgium Manchester, UK – 18 November 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, welcomes...

28 October 2021 – Yourgene’s Ranger Technology to be presented at Labroots webinar
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene’s Ranger® Technology to be presented at Labroots webinar Manchester, UK – 28 October 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Ranger®...

26 October 2021 – Half-year Trading update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Trading updateImproved H1 and year-to-date performance supporting higher full-year expectations Manchester, UK – 26 October 2021: Yourgene (AIM: YGEN), a leading international molecular...

19 April 2021 – Further National Microbiology Framework contract award
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Further National Microbiology Framework contract award Successful tender under Lot 4 (Clinical Laboratory Diagnostic Testing Services) valued at £15bn Manchester, UK – 19 April 2021: Yourgene (AIM:...

28 September 2021 – AGM Statement Investor presentation
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) AGM StatementInvestor presentation Manchester, UK - 28 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, will be holding its Annual General Meeting (AGM)...

10 September 2021 – Further re: DHSC contract secured to support COVID-19 surge testing
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Further re: DHSC contract secured to support COVID-19 surge testing Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract...

1 September 2021 – Yourgene Genomic Services receive ISO 15189:2012 accreditation
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services receive ISO 15189:2012 accreditation Validating its COVID-19 testing and sequencing services, providing assurance of compliance to international standards to deliver quality...

1 September 2021 – Notice of AGM and Annual Report 2021
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Notice of AGM and Annual Report 2021Investor presentation Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that the Notice of Annual...

19 August 2021 – Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene’s COVID-19 testing investment reaps rewardsDHSC contract secured to support COVID-19 surge testing Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular...

11 August 2021 – Audited Final results and unaudited Q1 business update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Audited Final results and unaudited Q1 business update Manchester, UK – 11 August 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its full year financial results for...

11 August 2021 – Earn-out Milestone, Issue of Equity & Total Voting Rights
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Earn-out Milestone, Issue of Equity & Total Voting Rights Manchester, UK 11 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces an issue of equity...

21 June 2021 – Second Strategic Partner for Coastal Genomics
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Second Strategic Partner for Coastal Genomics Manchester, UK – 21 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Inc., the Company’s...

18 June 2021 – Contract Award for the supply of DPYD testing kits to NHS Wales
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Contract Award for the supply of DPYD testing kits to NHS WalesEstimated to be worth £232,000 across two years Manchester, UK – June 2021: Yourgene (AIM: YGEN), the international molecular...

9 June 2021 – Multi-year licence and supply agreement with leading US precision medicine company
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Multi-year licence and supply agreement with leading US precision medicine company Manchester, UK – 9 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has...

19 May 2021 – Distribution Partnership for the Middle East and Africa
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Distribution Partnership for the Middle East and AfricaYourgene and Alliance Global launch partnership across multiple territories Manchester, UK – 19 May 2021: Yourgene (AIM: YGEN), the international...

18 May 2021 – Launch of IONA® Care NIPT service offering
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of IONA® Care NIPT service offeringExtended clinical menu to screen SCAs and AAs for pregnant women Manchester, UK – 18 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics...

17 May 2021 – Further testing service agreement for MyHealthChecked plc
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services to support MHC’s second Boots agreement for Day 2 & Day 8 testingfor international arrivals to the UK Manchester, UK – 17 May 2021: Yourgene (AIM: YGEN), the...

29 April 2021 – Full year Trading update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Full year Trading update10% year-on-year revenue growth Manchester, UK – 29 April 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the...

26 April 2021 – Further National Microbiology Framework contract awards
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Further National Microbiology Framework contract awards Successful tenders under Lots 2 & 3 valued at a total of £4bnYourgene one of only three companies to have been successfully awarded under all...

19 April 2021 – National Framework contract award for Covid-19 testing products and services
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) National Framework contract award for Covid-19 testing products and services Yourgene successful in UK-wide National Microbiology Framework (Lot 1) Manchester, UK – 19 April 2021: Yourgene (AIM: YGEN),...

6 April 2021 – Testing service agreement with MyHealthChecked plc
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Testing service agreement with MyHealthChecked plc Yourgene Genomic Services providing COVID-19 services to MHC’s new Boots partnership Manchester, UK – 6 April 2021: Yourgene (AIM: YGEN), the...

29 March 2021 – COVID-19 update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 update Approved provider of day two and day eight coronavirus testing for international arrivals, for both PCR and sequencing Manchester, UK – 29 March 2021: Yourgene (AIM: YGEN), the...

19 March 2021 – Twin Pregnancy study published using Yourgene’s IONA® Test
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Twin Pregnancy study published using Yourgene’s IONA® Test Manchester, UK – 19 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the paper published in the...

17 March 2021 – Appointment of VP of Sales North America
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Appointment of VP of Sales North AmericaStrategic hire to expand Yourgene’s commercial footprint in North America Manchester, UK – 17 March 2021: Yourgene (AIM: YGEN), the international molecular...

11 March 2021 – Yourgene Genomic Services portfolio expansion
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services portfolio expansion Cytox’s genoSCORETM-LAB test can predict the risk of developing Alzheimer’s disease Yourgene Genomic Services to run the array-based test at Citylabs 1.0 in...

1 March 2021 – First US Supply Agreement for Coastal Genomics’ Technology Signed with Major Strategic Partner
Yourgene Health plc ("Yourgene" or the "Group" or the "Company") First US Supply Agreement for Coastal Genomics’ Technology Signed with Major Strategic Partner Manchester, UK – 1 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group,...

22 February 2021 – Partnership with NPH
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Partnership with NPH To provide COVID-19 testing service for Leeds Bradford Airport Manchester, UK – 22 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces...

8 February 2021 – Trading update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Trading update Strong H2 momentum expected to deliver double-digit annual growth but below expectations Deferred revenue opportunities, investment in offering and further new initiatives expected to...

13 January 2021 – DPYD screening recommended in Belgium
Yourgene Health plc("Yourgene" or the "Group" or the "Company") DPYD screening recommended in Belgium Manchester, UK – 13 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the research article published on 11 January 2021, in...

11 January 2021 – Clarigene® SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Clarigene® SARS-CoV-2 Product Update and Partnerships with CityDoc and ReCoVa-19 Manchester, UK – 11 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that...

24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 update: approved provider for UK Government and response to new virus strain Manchester, UK – 24 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group,...

17 December 2020 – Half-year Report
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Report Manchester, UK – 17 December 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its...

2 December 2020 – DPYD kits recommended by NHS England
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DPYD kits recommended by NHS England Manchester, UK – 2 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the Clinical Commissioning Urgent Policy Statement,...

5 November 2020 – Directorate change
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate changeChief Scientific Officer appointment to drive new product development roadmap Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group,...

3 November 2020 – Partnership with Take2 Health Limited
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Partnership with Take2 Health LimitedYourgene to run genomic test for Nasopharyngeal Carcinoma (NPC) Screening in Taiwan Manchester, UK – 3 November 2020: Yourgene (AIM: YGEN), the international...

26 October 2020 – Half-year Trading update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Trading updateH1 year-on-year growth demonstrating the resilience of the Company Manchester, UK – 26 October 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group,...

23 October 2020 – CQC registration
Yourgene Health plc(“Yourgene Health” or the "Company") CQC registration Manchester, UK – 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission...

21 October 2020 – Yourgene Genomic Services collaboration with Cytox
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene Genomic Services collaboration with Cytox Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer’s disease Manchester,...

14 February 2020 – Medilink Award win for Outstanding Achievement
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Medilink Award win for Outstanding Achievement Manchester, UK – 14 February 2020:Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won the Outstanding...

12 October 2020 – Elucigene DPYD tests to be used routinely in Wales
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Elucigene DPYD tests to be used routinely in Wales Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapyDPYD tests screen patients to identify risk of severe side effects...

8 October 2020 – Strategic reproductive health partnership secured in Japan
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Strategic reproductive health partnership secured in Japan Manchester, UK – 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into...

7 October 2020 – IONA® Nx awarded contract with St George’s NHS Hospital
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) IONA® Nx awarded contract with St George’s NHS Hospital Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the...

3 August 2020 – CE-IVD Mark for Clarigene™ SARS-CoV-2 test
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) CE-IVD Mark for Clarigene™ SARS-CoV-2 test Manchester, UK – 3 August 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has achieved CE-IVD marking for its...

28 September 2020 – Launch of Yourgene Genomic Services
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of Yourgene Genomic Services Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an...

24 September 2020 – DPD reimbursement in Germany
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DPD reimbursement in Germany Manchester, UK – 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national...

22 September 2020 – AGM statement
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) AGM Statement Manchester, UK – 22 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting (AGM) at 4:00pm today. At the meeting,...

21 September 2020 – US distribution agreement for DPYD and other products
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) US distribution agreement for DPYD and other products Manchester, UK – 21 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has appointed...

3 September 2020 – IONA® Nx Launch
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) IONA® Nx Launch Manchester, UK – 3 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA® Nx NIPT workflow, the Company’s new innovative...

13 August 2020 – TGA approves IONA® Nx for sale in Australia
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) TGA approves IONA® Nx for sale in Australia Manchester, UK – 13 August 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its IONA® Nx NIPT workflow (‘IONA®...

5 August 2020 – Successful £16.15 million Placing & Close of Accelerated Bookbuild
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Successful £16.15 million Placing & Close of Accelerated Bookbuild Manchester, UK – 5 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to...

5 August 2020 – Result of Placing
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Result of Placing Manchester, UK – 5 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to confirm, further to the announcements made yesterday...

4 August 2020 – Proposed Acquisition and Placing to raise a minimum of £13 million
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Proposed Acquisition and Placing to raise a minimum of £13 million Manchester, UK – 4 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, today announces a...

28 July 2020 – Final Results
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Yourgene Health plc(“Yourgene”, the “Company” or the “Group”) Final Results Manchester, UK – 28 July 2020: Yourgene Health plc (AIM: YGEN), the international...

30 June 2020 – COVID-19 assay launched
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 assay launched Launch of Clarigene™ SARS-CoV-2 test (‘RUO’) Manchester, UK – 30 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the launch of its...

16 June 2020 – Collaboration in COVID-19 testing
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Collaboration in COVID-19 testing Supporting the effort to get Britain back to work Manchester, UK – 16 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a...

15 June 2020 – CE-IVD mark received for Illumina-based IONA® test
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) CE-IVD mark received for Illumina-based IONA® testNon-invasive prenatal screening test to launch as IONA® Nx Manchester, UK – 15 June 2020: Yourgene (AIM: YGEN), a leading international molecular...

26 May 2020 – Yourgene COVID-19 testing service launch and business update
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Yourgene COVID-19 testing service launch and business update Manchester, UK – 26 May 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has expanded its...

20 April 2020 – Year-end Trading update: Revenues increase 86%
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Year-end Trading update: Revenues increase 86% Manchester, UK – 20 April 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the year ended 31...

7 April 2020 – Presentation on ‘Adapting during crisis’
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Presentation on ‘Adapting during crisis’ Manchester, UK – 7 April 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that Hayden Jeffreys, Chief Operating...

25 March 2020 – Contract manufacturing agreement for COVID-19 diagnostic test
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Contract manufacturing agreement for COVID-19 diagnostic test Manchester, UK – 25 March 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the signing of an...

10 March 2020 – Acquisition of French distribution channel & Direct Subscription to raise £2.5m
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED WITHIN THEM, IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE...

17 February 2020 – CE Marking Technical File submission
Yourgene Health plc(“Yourgene” or the “Company”) CE Marking Technical File submission Manchester, UK – 17 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has submitted its CE Marking Technical File for the...

14 February 2020 – TGA approves DPYD for sale in Australia
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) TGA approves DPYD for sale in Australia Southern Cross, Yourgene’s Australian distributor, to sell the chemotoxicity diagnostic assay in the Territory Manchester, UK – 14 February 2020:Yourgene (AIM:...

2 December 2019 – Half-year Report
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Yourgene Health plc (“Yourgene”, the “Company” or the “Group”) Half-year Report Manchester, UK – 2 December 2019: Yourgene Health plc (AIM:...

29 November 2019 – Bionow Double Award Wins
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Bionow Double Award Wins Manchester, UK – 29 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won Bionow Investment Deal of Year and Bionow...

28 November 2019 – Opening of New Facilities and Corporate HQ
Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Opening of New Facilities and Corporate HQ Manchester, UK – 28 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the official opening of its...

31 October 2019 – Launch of Yourgene Flex™ Analysis Software
Yourgene Health plc(“Yourgene” or the “Group” or the “Company”) Launch of Yourgene Flex™ Analysis Software Manchester, UK 31 October 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has launched Yourgene Flex™ Analysis...

15 October 2019 – American Society of Human Genetics Annual Meeting attendance
Yourgene Health plc (“Yourgene” or the “Group”) American Society of Human Genetics Annual Meeting attendance Manchester, UK – 15 October 2019:Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it will be exhibiting at the...

14 October 2019 – Half year trading update
Yourgene Health plc (“Yourgene” or the “Group”) Half year trading update Manchester, UK – 14 October 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides a positive trading update for the six months to 30 September 2019....

26 September 2019 – CE-IVD Certification renewal
CE-IVD Certification renewal Manchester, UK – 26 September 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that in preparation for a 2020 product launch and as a contingency for BREXIT, the Company has successfully...

18 September 2019 – Launch of DPYD chemotoxicity diagnostic assay
Yourgene Health plc (“Yourgene” or the “Company”) Launch of DPYD chemotoxicity diagnostic assay Test to identify cancer patients at risk of lethal side effects from chemotherapy Manchester, UK – 18 September 2019: Yourgene (AIM: YGEN), a leading international...

20 August 2019 – Notice of AGM
Yourgene Health plc (“Yourgene” or the “Company”) Notice of AGM Manchester, UK – 20 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Annual General Meeting (AGM) will be held at 4:00pm on 17 September 2019 at...

16 August 2019 – Directorate Change Appointment of business development sector specialist as Non-executive Director
Yourgene Health plc (“Yourgene” or the “Company”) Directorate Change Appointment of business development sector specialist as Non-executive Director Manchester, UK – 16 August 2019:Yourgene (AIM: YGEN), a leading international molecular diagnostics group,...

29 July 2019 – Appointment of Director
Yourgene Health plc (“Yourgene”, the “Company” or the “Group”) Appointment of Director Manchester, UK – 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the...

10 July 2019 – Results for the Year Ended 31 March 2019, Business Update and Director Change
Yourgene Health plc (“Yourgene” or the “Company” or the “Group”) Results for the Year Ended 31 March 2019, Business Update and Director Change Manchester, UK – 10 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which...

9 July 2019 – Results for the Year Ended 31 March 2019 Business Update, Director Change
Yourgene Health plc(“Yourgene” or the “Company” or the “Group”) Results for the Year Ended 31 March 2019, Business Update and Director Change Manchester, UK – 10 July 2019: Yourgene Health plc (AIM: YGEN), the international...

24 June 2019 – Yourgene participates in key global conferences
Yourgene Health plc(“Yourgene Health” or the "Company") Yourgene participates in key global conferences Manchester, UK - 24 June 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services,...

25 April 2019 – Completion of Acquisition
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY...

17 April 2019 – Proposed acquisition of Delta Diagnostics (UK) Limited
Yourgene Health plc(“Yourgene” or the “Company”) Proposed acquisition of Delta Diagnostics (UK) Limited ("Elucigene")andProposed placing of a minimum of 92,682,928new Ordinary SharesandProposed subscription for 4,878,048new Ordinary Shares Highlights ● Proposed...

8 April 2019 – Full-year Trading Update
Yourgene Health plc (“Yourgene”, the “Company” or the “Group”) Full-year Trading Update Manchester, UK – 8 April 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading...

25 March 2019 – Yourgene raises IONA® test awareness in Egypt with British Ambassador (2)
Yourgene Health plc (“Yourgene” or the “Company”) Yourgene raises IONA® test awareness in Egypt with British Ambassador Manchester, UK – 25 March 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and...

18 February 2019 – Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder
Yourgene Health plc (“Yourgene” or the “Company”) Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder Manchester, UK – 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises...

8 January 2019 – High throughput NIPT solution for clinical laboratories
Yourgene Health plc (“Yourgene”, the “Company”) Yourgene launches Sage™ 32 plex High throughput NIPT solution for clinical laboratories Manchester, UK – 8 January 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group...

3 December 2018 – Half-year Results
Yourgene Health plc(“Yourgene”, the “Company” or the “Group”) Half-year Results Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited...

7 November 2018 – Change of Name to Yourgene Health plc & Change of Website Address
Premaitha Health plc(“Premaitha” or the “Group”) Change of Name to Yourgene Health plc&Change of Website Address Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and...

12 October 2018 – Trading Update & Notice of Results
Premaitha Health plc(“Premaitha” or the “Group”) Trading Update & Notice of Results Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the...

04 October 2018 – $1 million collaboration agreement
Premaitha Health PLC(“Premaitha,” the “Company” or the “Group”) $1 million collaboration agreementPartnership to provide genetic testing based on next generation sequencing for oncology Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international...

28 September 2018 – Proposed fundraise to raise approximately £2.5 million
THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC...

28 September 2018 – Full year results to 31 March 2018 and half-year trading update
Premaitha Health PLC(“Premaitha,” the “Company” or the “Group”) Full year results to 31 March 2018 and half-year trading update Manchester, UK – 28 September 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces its full year...

20 September 2018 – Senior Commercial Appointment and Anticipated Directorate Change
Premaitha Health plc(“Premaitha” or the “Group”) Senior Commercial Appointment and Anticipated Directorate Change Manchester, UK – 20 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the...

19 September 2018 – Legal Settlement and Licence Agreement with Illumina
Premaitha Health plc(“Premaitha” or the “Group”) Legal Settlement and Licence Agreement with Illumina Manchester, UK – 19 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce that the Group...

4 July 2018 – Board Changes
Premaitha Health plc(“Premaitha” or the “Group”) Board Changes Manchester, UK – 4 July 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Lyn Rees as Chief Executive Officer and Mr...

26 June 2018 – Collaboration with Abnova
Premaitha Health plc(“Premaitha” or the “Company”) Collaboration with Abnova Partnership to develop next generation sequencing capability for single cell analysis Manchester, UK – 26 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular...

13 June 2018 – Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award Manchester, UK – 13 June 2018: Premaitha Health plc (AIM:NIPT), a leading international molecular diagnostics group, is proud to announce that it...

11 June 2018 – Partnership agreement for DNA sequencing technology development
Premaitha Health plc(“Premaitha” or the “Company”) Partnership agreement for DNA sequencing technology development Manchester, UK – 11 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has signed an...

5 June 2018 – Premaitha signs NIPT partnership agreement in India
Premaitha Health plc(“Premaitha”, the “Company” or the “Group”) Premaitha signs NIPT partnership agreement in India Manchester, UK – 5 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

15 May 2018 – Premaitha expands footprint with new laboratories in Kenya and India
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha expands footprint with new laboratories in Kenya and India Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

15 May 2018 – Year-end Trading Update and £2.5m Fundraising
Premaitha Health plc (“Premaitha”, the “Company” or the “Group”) Year-end Trading Update and £2.5m Fundraising Revenues doubled in the year ended 31 March 2018 & An additional £2.5m funds raised Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a...

29 March 2018 – Premaitha to attend key industry conferences in Asia Pacific
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha to attend key industry conferences in Asia Pacific Manchester, UK – 29 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused...

26 March 2018 – Update on UK patent infringement claim received in September 2017
Premaitha Health plc(“Premaitha” or the “Company”) Update on UK patent infringement claim received in September 2017 Manchester, UK – 26 March 2018: Premaitha Health plc (AIM: NIPT), a leading international moleculardiagnostics group focused on non-invasive prenatal...

16 February 2018 – Premaitha secures market entry into Egypt
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha secures market entry into Egypt Manchester, UK – 16 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”),...

6 February 2018 – Premaitha raises awareness of the IONA® test at key conferences in the Middle East
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha raises awareness of the IONA® test at key conferences in the Middle East Manchester, UK – 6 February 2018: Premaitha Health plc (AIM: NIPT), a leading international...

5 February 2018 – Premaitha’s IONA® test approved for sale in Brazil
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha’s IONA® test approved for sale in Brazil Manchester, UK – 5 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group...

29 December 2017 – Half Year Results
Premaitha Health PLC(“Premaitha”, the “Company” or the “Group”)Half year resultsManchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the...

11 December 2017 – Premaitha secures four further laboratories in Europe
Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha secures four further laboratories in Europe Manchester, UK – 11 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on...

01 December 2017 – Premaitha CEO Wins Bionow Outstanding Contribution Award
Premaitha CEO Wins Bionow Outstanding Contribution Award Manchester, UK – 1 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), is proud to announce that its CEO,...

27 November 2017 – Middle East laboratory network expansion
Premaitha Health PLC(“Premaitha” or the “Company”) Middle East laboratory network expansion Manchester, UK – 27 November 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT),...

23 November 2017 – Premaitha signs new partner to offer NIPT solution in East Asia
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha signs new partner to offer NIPT solution in East Asia Manchester, UK – 23 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

21 November 2017 – Litigation First Instance Judgment
Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) Litigation First Instance Judgment Manchester, UK – 21 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing...

13 October 2017 – Commercial progress in the Middle East
Premaitha Health PLC(“Premaitha” or the “Company”) Commercial progress in the Middle East Manchester, UK – 13 October 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces...

29 September 2017 – Full year results to 31 March 2017 and half-year trading update
Issued on behalf of Premaitha Health plcManchester, UK: Friday, 29 Sept 2017 Premaitha Health PLC(“Premaitha,” the “Company” or the “Group”) Full year results to 31 March 2017 and half-year trading update Manchester, UK – 29 September 2017: Premaitha (AIM: NIPT), a...

19 September 2017 – Premaitha to offer NIPT in South Africa
Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha to offer NIPT in South Africa Manchester, UK – 19 September 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, announces...

7 September 2017 – Further patent infringement claims received from Illumina & Sequenom
Premaitha Health plc(“Premaitha” or the “Company”) Further patent infringement claims received from Illumina & Sequenom Manchester, UK – 7 September 2017: Premaitha Health plc (AIM: NIPT) announces that it has today received notification from Illumina and Sequenom...

29 August 2017 – Premaitha approved for Good Manufacturing Practice by ANVISA Brazil
Premaitha Health plc(“Premaitha” or the “Company”) Premaitha approved for Good Manufacturing Practice by ANVISA Brazil Manchester, UK – 29 August 2017: Premaitha Health plc (AIM: NIPT) announces that it has been approved for Brazilian Good Manufacturing Practice...

12 July 2017 – Investment Agreement Extension with Thermo Fisher Scientific
Premaitha Health Plc(“Premaitha”, the “Company” or the “Group”) Investment Agreement Extension with Thermo Fisher Scientific Manchester, UK – 12 July 2017 - Premaitha Health Plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive...

10 July 2017 – Premaitha announces two laboratory hub contracts in South East Asia
Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) Premaitha announces two laboratory hub contracts in South East Asia Manchester, UK – 10 July 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on...

3 July 2017 – Litigation Update
Premaitha Health PLC(“Premaitha” or the “Company”) Litigation Update Manchester, UK – 3 July 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides the following update on...

26 June 2017 – The IONA® test updated to include the first trimester combined test result
Premaitha Health PLC (“Premaitha” or the “Company”) The IONA® test updated to include the first trimester combined test result Manchester, UK – 26 June 2017: Premaitha Health, a leading international molecular diagnostics group focused on non-invasive prenatal testing...

16 June 2017 – Premaitha launches Sage™ prenatal screening solution in Hong Kong
Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha launches Sage™ prenatal screening solution in Hong Kong Manchester, UK – 16 June 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal...

5 June 2017 – India Business Update
Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) India Business Update Manchester, UK – 5 June 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to provide...

26 May 2017 – Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument
Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument Manchester, UK – 26 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international...

19 May 2017 – Premaitha welcomes NIPT recommendation in France
Premaitha Health PLC (“Premaitha” or the “Company”) Premaitha welcomes NIPT recommendation in France Haute Authorité de Santé recommends introduction of NIPT for high and intermediate risk women Manchester, UK – 19 May 2017: Premaitha Health plc...

12 May 2017 – Update Re. Swiss Customer
Premaitha Health PLC(“Premaitha” or the “Company”) Update Re. Swiss Customer Manchester, UK – 12 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that...

13 March 2017 – Premaitha Raises Awareness of the IONA® Test at Key International Medical Events
Premaitha Health PLC(“Premaitha” or the “Company”) Premaitha Raises Awareness of the IONA® Test at Key International Medical Events Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular...

27 February 2017 – Completion of Yourgene Acquisition, Issue of Shares and Director Appointments
Premaitha Health PLC(“Premaitha” or the “Company” or the “Group”) Completion of Yourgene Acquisition, Issue of Shares and Director Appointments Manchester, UK – 27 February 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group...

20 February 2017 – Middle East Business Update
Premaitha Health PLC(“Premaitha” or the “Company”) Middle East Business Update Manchester, UK – 20 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce significant commercial...

16 February 2017 – Publication of scientific paper on Premaitha’s IONA® test
Premaitha Health PLC(“Premaitha” or the “Company”) Publication of scientific paper on Premaitha’s IONA® test Manchester, UK – 16 February 2017: Premaitha Health, developer of a leading CE-marked non-invasive prenatal screening...

15 February 2017 – Issue of Equity
Premaitha Health plc("Premaitha" or the "Company") Issue of Equity Manchester, UK - 15 February 2017: Premaitha Health plc (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces that it has agreed to issue to Harwood Capital...

13 February 2017 – New partnership with major European diagnostics group
Premaitha Health PLC(“Premaitha” or the “Company”) New partnership with major European diagnostics group Manchester, UK – 13 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a...

7 February 2017 – Southern Europe Business Update
Premaitha Health PLC(“Premaitha” or the “Company”) Southern Europe Business Update Manchester, UK – 7 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a number of new customers through...

21 December 2016 – Half Year Results
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 21 December 2016 Premaitha Health PLC (“Premaitha” or “the Company”) Half Year Results Manchester, UK – 21 December 2016: Premaitha Health (AIM: NIPT), developer of a leading CE-marked non-invasive...

21 December 2016 – Conditional Acquisition of Yourgene Bioscience and Posting of Circular
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 21 December 2016 Premaitha Health PLC(“Premaitha” or “the Company”) Conditional Acquisition of Yourgene Bioscience and Posting of Circular Manchester, UK – 21 December 2016: Premaitha Health PLC (AIM:...

21 November 2016 – Premaitha establishes first service laboratory customer in Asia
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 21 November 2016 Premaitha Health PLC(“Premaitha” or “the Company”) Premaitha establishes first service laboratory customer in Asia the IONA® test to be offered in the Center for Medical Genomics,...

31 October 2016 – NHS to adopt NIPT for high risk women
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 31 October 2016 Premaitha Health PLC(“Premaitha” or “the Company”) NHS to adopt NIPT for high risk women Premaitha welcomes UK Govt. decision Manchester, UK – 31...

27 October 2016 – AGM Statement
Issued on behalf of Premaitha Health plcManchester, UK: Thursday, 27 Oct 2016 Premaitha Health Plc(“Premaitha” or the “Company”) AGM Statement Manchester, UK – 27 October 2016 – At the Annual General Meeting of Premaitha to be held...

30 September 2016 – Annual Results 2016
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 30 Sept 2016 Premaitha Health plc(“Premaitha” or the “Company”) Final results Manchester, UK – 30 September 2016 - Premaitha Health plc (AIM: NIPT), developer of the...

23 September 2016 – Investment agreement extension with Thermo Fisher Scientific
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 23 September 2016 RNS Number : 6625KPremaitha Health PLC23 September 2016 Premaitha Health Plc ("Premaitha" or the "Company") Investment agreement extension with Thermo Fisher Scientific Manchester, UK -...

4 July 2016 – Progress on anti-trust objections to litigation
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 4 July 2016 Progress on anti-trust objections to litigation Manchester, UK – 4 July 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked complete non-invasive prenatal screening...

27 June 2016 – Launch of MyNIPT™ Online Portal for the IONA® test
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 27 June 2016 Launch of MyNIPT™ Online Portal for the IONA® test Manchester, UK – 27 June 2016 - Premaitha Health PLC (AIM: NIPT), developer of the IONA® test, the leading CE-marked complete non-invasive...

22 April 2016 – Update on competitor patent litigation
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 22 April 2016 Premaitha Health plc(“Premaitha” or the “Company”) Update on competitor patent litigation Manchester, UK - 22 April 2016 - Premaitha Health PLC (AIM: NIPT, "Premaitha" or the...

20 April 2016 – Patent litigation rescheduled
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 20 April 2016 Premaitha Health plc(“Premaitha” or the “Company”) Patent litigation rescheduled Manchester, UK – 20 April 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked...

29 March 2016 – Premaitha announces tenth customer laboratory
Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 29 March 2016 Premaitha announces tenth customer laboratory Manchester, UK – 29 March 2016: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), announces that its French distributor,...

21 March 2016 – Premaitha Enters Middle East with Series of Regional Laboratory Hubs
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 21 March 2016 Premaitha Enters Middle East with Series of Regional Laboratory Hubs Manchester, UK – 21 March 2016: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), developer of the...

11 March 2016 – Premaitha wins at North West Business Masters Awards 2016
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 11 March 2016 Premaitha Health plc(“Premaitha” or the “Company”) Premaitha wins at North West Business Masters Awards 2016 Manchester, UK – 11 March 2016: Premaitha Health plc (AIM: NIPT), the company...

9 March 2016 – Premaitha signs distribution agreement with GeNext in Russia
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 9 March 2016 Premaitha Health plc(“Premaitha” or the “Company”) Premaitha signs distribution agreement with GeNext in Russia Manchester, UK – 9 March 2016: Premaitha Health plc (AIM: NIPT), the...

3 February 2016 – Premaitha Health partners with Visional Medical to provide the IONA® test to pregnant women in India
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 3 February 2016 Premaitha Health partners with Visional Medical to provide the IONA® test to pregnant women in India Manchester, UK and Chennai, India – 3 February 2016 – Premaitha Health plc (AIM:...

2 February 2016 – Premaitha Health partners with Leeds Teaching Hospitals NHS Trust to offer pregnant women safer non-invasive prenatal screening service
Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 2 February 2016 Premaitha Health partners with Leeds Teaching Hospitals NHS Trust to offer pregnant women safer non-invasive prenatal screening service Manchester and Leeds, UK – 2 February 2016 –...

27 January 2016 – Premaitha Health signs two new customers for its clinical laboratory NIPT screening service
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 27 January 2016 Premaitha Health signs two new customers for its clinical laboratory NIPT screening service Manchester, UK – 27 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the...

26 January 2016 – Update on UK Litigation Timing
Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 26 January 2016 Update on UK Litigation Timing Manchester, UK – 26 January 2016: Premaitha Health PLC (“Premaitha” or “the Company”; AIM: NIPT) provides investors with visibility of the timelines...

15 January 2016 – Premaitha Health welcomes recommendation for NHS provision of non-invasive prenatal testing
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 15 January 2016 Premaitha Health welcomes recommendation for NHS provision of non-invasive prenatal testing National Screening Committee recommendation will enable more pregnant women to benefit from...

8 January 2016 – Update on competitor patent litigation
Manchester, UK – 8 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal (NIPT) in vitro diagnostic kit, notes that Illumina, Inc. has today announced two patent...

5 January 2016 – Premaitha Health launches Workflow Manager system for the IONA® test to support clinical laboratory customers
Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 5 January 2016 Premaitha Health launches Workflow Manager system for the IONA® test to support clinical laboratory customers Comprehensive clinical sample and patient data tracking from receipt to...

14 December 2015 – Results for the half year ended 30 September 2015
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 14 December 2015 Results for the half year ended 30 September 2015 Manchester, UK – 14 December 2015: Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”)...

14 December 2015 – Premaitha Health signs Investment Agreement with Thermo Fisher Scientific
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 14 December 2015 Premaitha Health signs Investment Agreement with Thermo Fisher Scientific Manchester, UK – 14 December 2015: Premaitha Health PLC (AIM: NIPT, “Premaitha” or the...

2 December 2015 – Premaitha establishes the first IONA® testing service in France at LaboSud
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 2 December 2015 Premaitha establishes the first IONA® testing service in France at LaboSud Manchester, UK and Montpellier, France – 2 December 2015 – Premaitha Health plc (AIM: NIPT, “Premaitha” or...

12 November 2015 – Independent, multi-centre clinical study of the IONA® test in high risk pregnancies shows 100% detection of trisomies and 0% false positives
Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 12 November 2015 Independent, multi-centre clinical study of the IONA® test in high risk pregnancies shows 100% detection of trisomies and 0% false positives Study verifies performance of the test and...

14 October 2015 – Premaitha opens dedicated clinical laboratory with expanded capacity to meet demand for IONA® test service
Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 14 October Premaitha opens dedicated clinical laboratory with expanded capacity to meet demand for IONA® test service Manchester, UK – 14 October 2015 – Premaitha Health plc (AIM:...

13 October 2015 – In-house Antenatal reflex DNA screening for Down’s syndrome, trisomy 18 and trisomy 13: a world first
Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 13 October 2015 RNS 7.00am Tuesday 13th October 2015 In-house Antenatal reflex DNA screening for Down’s syndrome, trisomy 18 and trisomy 13: a world first The Wolfson Institute of Preventive Medicine...

12 October 2015 – Independent performance study of the IONA® test published
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 12 October 2015 Independent performance study of the IONA® test published Further verification of the test showing 100% of trisomies detected and 0% false positives from 242 maternal blood samples...

2 October 2015 – Premaitha appoints Antisel SA to distribute the IONA® test in Greece
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 2 October 2015 Premaitha appoints Antisel SA to distribute the IONA® test in Greece Manchester, UK and Athens, Greece – 2 October 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT),...

1 October 2015 – Illumina Patent Infringement Proceedings Update
Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 1 October 2015 Illumina Patent Infringement Proceedings Update Manchester, UK – 1 October 2015 - Premaitha Health plc ("Premaitha" AIM: NIPT) an innovative molecular diagnostics company employing the...

22 September 2015 – Premaitha signs first non-European partnership with Servicios Genéticos OriGen to provide the IONA® test for pregnant women in Chile
Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 22 September 2015 Premaitha signs first non-European partnership with Servicios Genéticos OriGen to provide the IONA® test for pregnant women in Chile Manchester, UK and Santiago, Chile – 22 September...

2 July 2015 – Completion of placing to raise £8 million
Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 2 July 2 July 2015Premaitha Health plc (“Premaitha” or the “Company”) Completion of placing to raise £8 million Premaitha (AIM: NIPT) has successfully completed the...

2 July 2015 – Proposed placing to raise approximately £8 million
Not for publication, distribution or release directly or indirectly, in whole or in part, in or into the United States, Canada, Australia, New Zealand, Japan, the Republic of Ireland or the Republic of South Africa or in any other jurisdiction in which offers or sales...

24 June 2015 – New IONA® test clinical data showcased
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 24 June 2015 New IONA® test clinical data showcased at the World Congress in Fetal Medicine Manchester, UK - 24 June 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM:...

22 June 2015 – New contract for IONA® test
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 22 June 2015 New contract for IONA® test Manchester and Leeds, UK – 22 June 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked test...

15 June 2015 – Clinical and performance data from the IONA® test to be presented at the World Congress in Fetal Medicine, Crete
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 15 June 2015 Clinical and performance data from the IONA® test to be presented at the World Congress in Fetal Medicine, Crete Manchester, UK 15 June 2015 – Premaitha Health plc (“Premaitha”, AIM: NIPT)...

6 July 2015 – Premaitha Health receives CQC accreditation for new NIPT clinical service laboratory to support IONA® test customers
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 6 July 2015 Premaitha Health receives CQC accreditation for new NIPT clinical service laboratory to support IONA® test customers Manchester, UK – 6 July 2015 – Premaitha Health plc (“Premaitha” or “the...

4 June 2015 – Directorate Change
Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 4 June 2015 Directorate Change Manchester, UK – 4 June 2015: Premaitha Health plc (“Premaitha” or “the Company”; AIM: NIPT) announces the appointment of Barry Hextall, CGMA, MBA, CertIOD as Chief...

22 May 2015 – Premaitha Health wins Medical & Lifescience Award
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 22 May 2015 Premaitha Health wins Medical & Lifescience Award at Insider’s Made in the North West Awards Manchester, UK – 22 May 2015 – Premaitha Health plc (“Premaitha”, AIM: NIPT) has been awarded...

5 May 2015 – Premaitha files robust defence with UK’s High Court in response to alleged infringement of NIPT patents
Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 5 May 2015 Premaitha files robust defence with UK’s High Court in response to alleged infringement of NIPT patents Manchester, UK – 5 May 2015 – Premaitha Health plc (“Premaitha”, AIM: NIPT) announces...

31 March 2015 – Centrum Badan DNA partners with Premaitha Health to offer the IONA® test in Poland
The two companies will work closely together as they establish Centrum Badan as Premaitha’s preferred partner laboratory within Poland.
The IONA® test is the first CE-marked in vitro diagnostic (IVD) product for NIPT, enabling genetic laboratories such as Centrum Badan to offer NIPT in-house. It uses next-generation sequencing (NGS) technology to estimate the risk of a fetus having serious genetic disorders such as Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13) by analysing cell-free fetal DNA from a sample of maternal blood. The IONA test® has a higher detection rate and lower false positive rate than the current combined test available to pregnant women in Poland.

23 March 2015 – Leading London NHS trust teams up with Premaitha Health to create the UK’s first Centre of Excellence for non-invasive prenatal screening
Issued on behalf of Premaitha Health plc and St George’s University Hospitals NHS Foundation Trust Manchester, UK and London, UK: Monday, 23 March 2015 Leading London NHS trust teams up with Premaitha Health to create the UK’s first Centre of Excellence for...

16 March 2015 – Premaitha Health and Esperite NV sign a collaboration agreement for NIPT provision in Europe
Issued on behalf of Premaitha Health plc and Esperite NV Manchester, UK and Zutphen, The Netherlands: Monday, 16 March 2015 Premaitha Health and Esperite NV sign a collaboration agreement for NIPT provision in Europe Manchester, UK and Zutphen, the Netherlands – 16...

16 March 2015 – Notice of Patent Infringement Proceedings
Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 16 March 2015 PRESS RELEASE Notice of Patent Infringement Proceedings Manchester, UK – 16 March 2015 – Premaitha Health plc (“Premaitha” AIM: NIPT) an innovative molecular diagnostics company employing...

5 February 2015 – Premaitha Health Launches the IONA® test, the First Ever CE-marked NIPT Product for Pregnant Women
Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 5 February 2015 Premaitha Health plc (“Premaitha” or the “Company”, AIM: NIPT), an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for...

30 January 2015 – Premaitha Health Receives ISO 13485:2003 Certification and Meets Annex IV of the In Vitro Diagnostic Medical Device Directive
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 30 January 2015 Achieves significant milestones in preparing for CE-mark and commercial launch Premaitha Health plc (”Premaitha” or the “Company”, AIM: NIPT), an innovative molecular diagnostics company...

28 November 2014 – Premaitha Health Wins Bionow Investment Deal of the Year Award
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 28 November 2014 £7.2m reverse listing to AIM enabling commercialisation of ground-breaking test for Down’s syndrome Manchester, UK – 28 November 2014 – Premaitha Health (‘Premaitha’) (AIM: NIPT), an...

6 November 2014 – Premaitha Health Prepares for Launch of the IONA® test with Key Commercial Appointment
Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 6 November 2014 Premaitha Health (‘Premaitha’) (AIM: NIPT), an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT),...

4 July 2014 – Premaitha Looks to Deliver Diagnostic Test Product to Improve Prenatal Screening Globally
Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 4 July 2014 The Premaitha business Today, Premaitha, located at the Manchester Science Park, UK has commenced trading on London Stock Exchange platform AIM. The Company has raised £7.2m by way of Placing...

13 June 2014 – Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally
UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health, based in Manchester’s Science Technology Park announces today that it has agreed terms to join ViaLogy plc, an investment company quoted on the London Stock Exchange. Subject to ViaLogy...
Our News
Yourgene have worked closely with Key Opinion Leaders, high profile partners, customers and market renowned experts within their chosen fields to develop a series of Your Expert papers. We aim to cover a range of different topics and content relevant to the portfolio of applications that Yourgene operates in. We aspire that these papers are relevant, informative, educational and add value.
Roll your mouse over the document to download.
Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice
Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.
Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice
Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.
Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice
Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.
Clinical Performance
This content can be added here or for more complex layouts link to a layout in the Divi Library by clicking on the ‘dynamic content’ icon top right in this editor window.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.
Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.
Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.
Resources
This content can be added here or for more complex layouts link to a layout in the Divi Library by clicking on the ‘dynamic content’ icon top right in this editor window.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.
Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.
Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.